Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mammography Imbroglio Makes Case For More Stakeholder Input In CER - AHRQ's Clancy

This article was originally published in The Pink Sheet Daily

Executive Summary

The AHRQ director reflected on lessons to be learned from the negative public reaction to the U.S. Preventive Services Task Force's opinion on mammography screening.

You may also be interested in...



Discussing CER Communications Asymmetry Is Putting The Cart Before The Horse – UPenn’s Caplan

Current comparative research lacks firm quality data standards, including what would be considered accurate CER. Caplan notes that in today’s research environment, standards are determined by the peer review process and have no consistent application and no regulation. Before asymmetry can be addressed, these standards need to be determined.

Senate Considers Revised Comparative Effectiveness Plan In Reform Bill

Comparative effectiveness research led by a non-government institute with funding from public and private sources, as envisioned by Sen. Max Baucus, D-Mont., is among the provisions for health care reform that are being debated by the Senate, but some changes to CER provisions were made as the bill moved from the Finance Committee to its current iteration on the Senate floor

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Topics

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel